Gan & Lee Pharmaceuticals' high P/S ratio may not be justifi...
Gan & Lee Pharmaceuticals' high P/S ratio may not be justified due to its slow revenue growth and the industry's better growth forecast. Investors may be disappointed if the P/S falls in line with the growth outlook, posing a significant risk of share price decline.
Gan & Lee Pharmaceuticals. (SHSE:603087) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment